Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Brand Name :
N/A
Synonyms :
tesmilifene
Class :
CYP3A4 Inhibitors, Antiplatelet agents
Dosage forms and strengths:Â
This is used for research/investigation purposeÂ
In vivo studies suggest this drugs act as adjuvant therapy for breast cancer
Not determined Â
Refer to the adult dosing regimen
Actions and spectrum:Â
Tesmilifene acts as a modulator of multidrug resistance (MDR), which potentially enhances the efficacy of chemotherapy. Â
Frequency not definedÂ
FatigueÂ
NauseaÂ
Weight gainÂ
Skin rashÂ
Erectile dysfunctionÂ
HeadachesÂ
Black box warning:Â
None Â
Contraindication/Caution:Â
The drug is contraindicated in following situations:Â Â
HypersensitivityÂ
Severe Liver DysfunctionÂ
Pregnancy and breastfeedingÂ
Pregnancy Warnings:Â Â
Pregnancy category: N/AÂ Â
Lactation:Â Â
Excretion of the drug in human breast milk is unknown Â
Pregnancy Categories:Â Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.   Â
<b>Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.   Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.   Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.   Â
Category N: There is no data available for the drug under this category.Â
Pharmacology:Â
The pharmacology of tesmilifene is associated with its role as a modulator of drug resistance.  Â
Pharmacodynamics:Â
Tesmilifene is involved in overcoming resistance which enhances the sensitivity of cancer cells to chemotherapy.Â
Pharmacokinetics:Â
Limited information available on ADME. Â
Administration:Â
The route of administration is not fully known.Â
Â
Patient information leaflet:Â
Generic Name: tesmilifeneÂ
Why do we use tesmilifene?Â
The drug has been studied for its role useful in management of breast cancer. Â